ArticleJournal of biological methods2019
Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry.
Article in Journal of biological methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.Journal for immunotherapy of cancer · 2021Trial
- Expression of TIM-3 and Gal-9 Immune Checkpoints in Chronic Lymphocytic Leukemia: The Potential Role of Interleukin-27.Current issues in molecular biology · 2025Article
- In Vitro Generated Equine Hepatic-Like Progenitor Cells as a Novel Potent Cell Pool for Equine Metabolic Syndrome (EMS) Treatment.Stem cell reviews and reports · 2023Article
- Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.The Journal of clinical investigation · 2022Article
- Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines.Advanced drug delivery reviews · 2022Review
- On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy.Biosensors · 2021Review
- Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.Journal for immunotherapy of cancer · 2021Article
- Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.Cancer immunology, immunotherapy : CII · 2021Article
- Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint.Journal of medicinal chemistry · 2020Article
- Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research.Frontiers in molecular biosciences · 2020Review
- Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells.Journal of biological methods · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As checkpoint inhibitor immunotherapies gain traction among cancer researchers and clinicians, the need grows for assays that can definitively phenotype patient immune cells. Herein, we present an 8-color flow cytometry panel for lineage and immune checkpoint markers and validate it using healthy human donor peripheral blood mononuclear cells (PBMCs). Flow cytometry data was generated on a BD LSR Fortessa and supported by Luminex multiplex soluble immunoassay. Our data showed significant variation between donors at both baseline and different stages of activation, as well as a trend in increasing expression of checkpoint markers on stimulated CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.